Table 1 Baseline characteristics of the 2,656 participants of HYVET for whom the frailty index was calculable, by treatment group
Placebo | Active | |
|---|---|---|
n | 1,324 | 1,332 |
Age (yrs), mean (SD) | 83.4 (3.0) | 83.6 (3.2) |
Male | 520 (39.3%) | 526 (39.5%) |
Female | 804 (60.7%) | 806 (60.5%) |
Body mass index* | ||
Underweight | 39 (3%) | 58 (4%) |
Normal weight | 587 (44%) | 605 (46%) |
Overweight | 566 (43%) | 530 (40%) |
Obese | 132 (10%) | 138 (10%) |
Sitting SBP, mean (SD) | 173.1 (8.9) | 173.3 (8.8) |
Sitting DBP, mean (SD) | 90.0 (8.9) | 89.9 (8.8) |
Standing SBP, mean (SD) | 168.0 (11.8) | 168.2 (11.9) |
Standing DBP, mean (SD) | 87.9 (9.9) | 88.1 (9.8) |
Cardiovascular disease, n (%) | 177 (13.4%) | 159 (11.9%) |
Antihypertensive treatment prior to entry into the trial, n (%) | 830 (62.7%) | 828 (62.2%) |
Mini Mental State Examination, median (IQR) | 26.0 (22–28) | 26.0 (22–28) |
Frailty Index, median (IQR) | 0.17 (0.11–0.24) | 0.16 (0.11–0.24) |